Navigation Links
FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
Date:11/30/2007

ine is not fully known, scientists believe its effects on depression and anxiety symptoms, as well as its effect on pain perception, may be due to increasing the activity of serotonin and norepinephrine in the central nervous system.

Important Safety Information

Cymbalta is approved to treat major depressive disorder and generalized anxiety disorder and manage diabetic peripheral neuropathic pain. Antidepressants can increase suicidal thoughts and behaviors in children, adolescents and young adults. Patients should call their doctor right away if they experience new or worsening depression symptoms, unusual changes in behavior, or thoughts of suicide. Be especially observant within the first few months of treatment or after a change in dose. Cymbalta is approved only for adults 18 and over.

Cymbalta is not for everyone. Patients should not take Cymbalta if they have recently taken a type of antidepressant called a monoamine oxidase inhibitor (MAOI), are taking Mellaril(R) (thioridazine) or have uncontrolled glaucoma. Patients should speak with their doctor about any medical conditions they may have, including liver or kidney problems or glaucoma. Patients should tell their doctor about all of their medicines, including those for migraine to avoid a potentially life-threatening condition, and NSAIDs, aspirin or blood thinners due to an increased risk of bleeding. They also should talk to their doctor about their alcohol consumption. Patients should consult with their doctor before stopping Cymbalta or changing the dose and if they are pregnant or nursing.

Patients taking Cymbalta may experience dizziness or fainting upon standing. The most common side effects of Cymbalta include nausea, dry mouth, sleepiness and constipation. This is not a complete list of side effects.

For full Patient Information, visit http://www.cymbalta.com.

For full Prescribing Information, including B
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. New Data Suggest Cymbalta(R) Reduced Pain in Fibromyalgia Patients With and Without Depression
4. Abbotts ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study
5. SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia
6. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
9. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
10. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
11. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , September 23, 2014 ... has announced the addition of the  "Large ... to their offering.  ,     ... drug delivery market holds significant potential for ... vials and painful needles to the modern-day ...
(Date:9/23/2014)... , Sept. 23, 2014  MEDIMETRIKS PHARMACEUTICALS ... William Resnick have been elected to ... Mr. Lary, who will serve on ... and investment experience to the Company.  Mr. Lary ... Advisors, LLC, a leading institutional investment firm.  Mr. ...
(Date:9/23/2014)... 2014  KemPharm, Inc., a clinical-stage specialty pharmaceutical ... proprietary new molecular entity (NME) prodrugs, announced today ... from Health Canada to begin clinical trials in ... product candidate KP201 (benzhydrocodone hydrochloride and acetaminophen).  KP201 ... moderate to moderately severe pain. The Health Canada ...
Breaking Medicine Technology:Large Volume Wearable Injectors - 2nd Edition 2Large Volume Wearable Injectors - 2nd Edition 3Large Volume Wearable Injectors - 2nd Edition 4Large Volume Wearable Injectors - 2nd Edition 5Medimetriks Pharmaceuticals, Inc. Welcomes Independent Directors Andrew Lary and William Resnick to its Board of Directors 2KemPharm Receives Health Canada Approval to Begin KP201 Clinical Trials in Canada 2KemPharm Receives Health Canada Approval to Begin KP201 Clinical Trials in Canada 3
(Date:9/23/2014)... analysis of published studies found that FDG-PET technology ... benign disease in regions where infections like histoplasmosis ... lesions suspicious for cancer could lead to unnecessary ... complications and mortality. , Histoplasmosis and other ... often concentrated in bird droppings and are found ...
(Date:9/23/2014)... 2014 World of Home Fitness is ... Most recently, the gym has been raising money to ... Throughout the year, World of Home Fitness has participated ... , Over the summer, World of Home Fitness raised ... Ageless Fitness program, participants helped feed seniors "one rep ...
(Date:9/23/2014)... As a consumer in today’s world, ... It’s difficult to trust testimonials that are supplied by ... manipulate their customers into saying anything. , Consumer advocacy ... to lack in depth coverage on a particular market ... to fix this issue and focus on exposing the ...
(Date:9/23/2014)... HealthDay Reporter TUESDAY, Sept. ... got paid for providing better care, not ... informed health choices. A new report suggests that,s ... report, from the IMS Institute for Healthcare Informatics in Parsippany, ... to alter the delivery of health care and use of ...
(Date:9/23/2014)... Genomic medicine is rapidly developing, bringing with its ... and optimize prevention and treatment interventions. Genetic ... immunodeficiency virus (HIV) and hepatitis c virus (HPC), ... be used to screen for an individual,s susceptibility ... treatments for addiction. , While there appear to ...
Breaking Medicine News(10 mins):Health News:Study questions accuracy of lung cancer screens in some geographic regions 2Health News:World of Home Fitness Supports Meals on Wheels 2Health News:Consumer Health Reports Debuts Revolutionary Review Website 2Health News:Report Identifies Game Changers for U.S. Health Care 2Health News:Report Identifies Game Changers for U.S. Health Care 3Health News:NYU-Mount Sinai Beth Israel study explores drug users' opinions on genetic testing 2
... anxiety, experts say, , , FRIDAY, May 15 (HealthDay News) -- ... associated with heights, a job interview or getting lost in ... and tension that affects twice as many women as men ... quality of life. , But a new study published in ...
... a vaccine , , FRIDAY, May 15 (HealthDay News) -- ... has yet to run its current course in the ... closed Thursday after dozens of flu-like infections surfaced and ... ventilator, according to published reports. , New York Mayor ...
... LONDON, May 15 Tourist figures are returning to ... major carrier,DialAFlight. Despite continued warnings from the press, governments ... from booking,holidays to ,at-risk, areas of the globe. , ... which carries half a million customers each,year - reports ...
... The Mobile Massage Team ( www.mobilemassageteam.com ), a ... programs, promotional events, and special affairs, today announced that the ... Unites(R) for Living Beyond Breast Cancer ( http://www.lbbc.org ... a.m. to 12:00 p.m. on the steps of the Philadelphia ...
... Paul Capital Healthcare today announced that New York-based partner, ... forms of financing at the 2009 BIO International Convention. ... non-dilutive financing options that can meet the needs of ... and Other Non-traditional Forms of Financing," is scheduled for ...
... Palatin Technologies, Inc. (NYSE Amex: PTN ) announced ... Palatin reported net income of $0.1 million, or $0.00 per basic ... to a net loss of $5.1 million, or $0.06 per basic ... revenues in the quarter ended March 31, 2009 were $5.2 million, ...
Cached Medicine News:Health News:Fear Response May Stem From Protein in Brain 2Health News:Swine Flu Closes 3 Schools in NYC 2Health News:Swine Flu Closes 3 Schools in NYC 3Health News:Swine Flu Closes 3 Schools in NYC 4Health News:Swine Flu Closes 3 Schools in NYC 5Health News:Swine Flu Closes 3 Schools in NYC 6Health News:Swine Flu Closes 3 Schools in NYC 7Health News:Swine Flu Closes 3 Schools in NYC 8Health News:Swine Flu Closes 3 Schools in NYC 9Health News:Swine Flu Closes 3 Schools in NYC 10Health News:DialAFlight Announce Bookings Upsurge After Swine Scare 2Health News:Paul Capital Healthcare to Participate in Panel on Non-Traditional Forms of Financing 2Health News:Palatin Technologies, Inc. Reports Fiscal Year 2009 Third Quarter Results; Teleconference and Webcast to be held on May 15, 2009 2Health News:Palatin Technologies, Inc. Reports Fiscal Year 2009 Third Quarter Results; Teleconference and Webcast to be held on May 15, 2009 3Health News:Palatin Technologies, Inc. Reports Fiscal Year 2009 Third Quarter Results; Teleconference and Webcast to be held on May 15, 2009 4Health News:Palatin Technologies, Inc. Reports Fiscal Year 2009 Third Quarter Results; Teleconference and Webcast to be held on May 15, 2009 5Health News:Palatin Technologies, Inc. Reports Fiscal Year 2009 Third Quarter Results; Teleconference and Webcast to be held on May 15, 2009 6
Design allows for easy-one hand application to provide support and immobilization of the wrist while preserving finger mobility...
... The Hand and Wrist Cryo/Cuff combines the ... and swelling, and cold to minimize pain. The ... be repositioned for desired hand coverage. ,For added ... and can be removed if a wider range ...
... The Blue Line UNO Splint fits small, ... Softy cushioned two-part design includes both dorsal and ... and extension. Recommended for those experiencing symptoms of ... Ideal for busy clinics - stock one splint ...
... 3-Point® Polycentric Hinged Ulnar Deviation Splint uses ... the hand with ulnar deviation at the ... grasp or pinch. Radial and ulnar polycentric ... unimpeded flexion and extension. Padded, malleable finger ...
Medicine Products: